Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Sema4 Holdings — Q4 2021 Earnings Presentation
14 slides from Genedx's earnings presentation, Mar 14, 2022
Slide 1: Q4 2021 Earnings Presentation
Q4 2021 Earnings Presentation March 2022 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, co
Slide 3: Recent Business Highlights
Recent Business Highlights 4Q 20211 revenue growth of 24%2 4Q 2021 resulted volume growth of 37%2 Signed definitive agreement to acquire GeneDx Entered into an agreement for a $200 million private placement from leading investors, including Pfizer3 Initiated FY2022 revenue guidance of $215 – 225 mil
Slide 4: Strong Close to FY2021
4 Resulted approximately 83,000 tests excluding COVID-19 Implies volume growth of 37% YoY and 19% QoQ Generated $58 million of revenue 24% growth YoY excluding COVID-19 revenue1 $401 million in Cash & Cash Equivalents as of 12/31/21 4Q Resulted Volume 4Q Total Revenue 4Q Balance Sheet Strong Close t
Slide 5: Traction with Health Systems Remains Robust
Traction with Health Systems Remains Robust Founder Health System Consortium • Held 1st Founder Health System Consortium • Network is building a combined point of view that will help the industry understand the power of shared data • Meetings will be held quarterly NorthShore • Continuing to scale p
Slide 6: Q4 GAAP Financial Highlights
Q4 GAAP Financial Highlights 4Q 2020 4Q 2021 Total Revenue $64.0 $57.8 Revenue (ex- COVID) $38.2 $47.3 Gross (Loss) Profit ($5.7) ($2.8) Gross Margin (9%) (5%) GAAP Net (Loss) ($125.7) ($40.2) 1 3 months ended 12/31/21. Certain expenses were previously misclassified as cost of services. These expens
Slide 7: Q4 Non-GAAP Financial Highlights
Q4 Non-GAAP Financial Highlights 4Q 2020 4Q 2021 Total Adjusted EBITDA2 ($31.3) ($73.0) Adjusted Gross Profit (Loss)3 $20.4 ($0.2) Adjusted Gross Margin4 32% 0% 4Q 20211 – Financial Highlights USD Millions 4Q 20211 – Segment Mix % Revenue 1 3 months ended 12/31/21 2 Adjusted EBITDA is a non-GAAP fin
Slide 8: FY2022 Guidance
8 Will exceed 20% growth YoY Implies resulted volume of 350,000+ Adjusted gross margin to exceed 10% FY22 Resulted Volume FY2022 Guidance (excludes impact of pending GeneDx acquisition) FY22 Revenue Expects total revenues in the range of $215-225 million Guidance excludes COVID-19 revenue FY22 Gross
Slide 9: Thank you
Thank you
Slide 10: Appendix
Appendix
Slide 11: Historical COVID Revenue Mix
1Q20 2Q20 3Q20 FY20 1Q21 2Q21 3Q21 4Q21 Diagnostic Test 99% 93% 84% 79% 73% 87% 86% 79% COVID 0% 6% 14% 18% 25% 8% 10% 18% Other 1% 1% 2% 2% 2% 4% 4% 3% 1 Certain periods do not add to 100% due to rounding Historical COVID Revenue Mix % of Total Revenue1 11
Slide 12: Non-GAAP Gross Margin Reconciliation
Non-GAAP Gross Margin Reconciliation USD in thousands 12 1Q 2Q 3Q 4Q FY 1Q 2Q 3Q 4Q FY Revenue 46,655 30,102 38,608 63,957 179,322 64,201 47,015 43,178 57,801 212,195 Cost of Service 37,138 34,505 34,022 69,631 175,296 68,524 48,179 51,487 60,607 228,797 Gross (Loss) Profit 9,517 (4,403) 4,586 (5,67
Slide 13: Non-GAAP EBITDA Reconciliation
Non-GAAP EBITDA Reconciliation USD in thousands 13 1Q 2Q 3Q 4Q FY 1Q 2Q 3Q 4Q FY Net Profit (Loss) (26,990) (32,052) (56,615) (125,683) (241,340) (191,775) (46,161) 32,731 (40,185) (245,390) Interest expense, net (1) 240 539 574 615 1,968 702 713 656 685 2,756 Depreciation and amortization 2,398 2,6
Slide 14: SMFR Semat
SMFR Semat Nasdaq Listed sema4